Menadione reduces CDC25B expression and promotes tumor shrinkage in gastric cancer

• Published in: Therapeutic advances in gastroenterology 2020-01, Vol.13, p.1756284819895435-1756284819895435
• Main Authors: Bona, Amanda Braga, Calcagno, Danielle Queiroz, Ribeiro, Helem Ferreira, Muniz, José Augusto Pereira Carneiro, Pinto, Giovanny Rebouças, Rocha, Carlos Alberto Machado, Lacreta Junior, Antonio Carlos Cunha, de Assumpção, Paulo Pimentel, Herranz, Juan Antonio Rey, Burbano, Rommel Rodriguez
• Format: Article
• Language: English
• Subjects: Cell cycle; Cell division; Gastric cancer; Gastroenterology; Original Research
• ISSN: 1756-2848; 1756-283X; 1756-2848
• DOI: 10.1177/1756284819895435

Background: Gastric cancer is one of the most incident types of cancer worldwide and presents high mortality rates and poor prognosis. MYC oncogene overexpression is a key event in gastric carcinogenesis and it is known that its protein positively regulates CDC25B expression which, in turn, plays an essential role in the cell division cycle progression. Menadione is a synthetic form of vitamin K that acts as a specific inhibitor of the CDC25 family of phosphatases. Methods: To better understand the menadione mechanism of action in gastric cancer, we evaluated its molecular and cellular effects in cell lines and in Sapajus apella, nonhuman primates from the new world which had gastric carcinogenesis induced by N-Methyl-N-nitrosourea. We tested CDC25B expression by western blot and RT-qPCR. In-vitro assays include proliferation, migration, invasion and flow cytometry to analyze cell cycle arrest. In in-vivo experiments, in addition to the expression analyses, we followed the preneoplastic lesions and the tumor progression by ultrasonography, endoscopy, biopsies, histopathology and immunohistochemistry. Results: Our tests demonstrated menadione reducing CDC25B expression in vivo and in vitro. It was able to reduce migration, invasion and proliferation rates, and induce cell cycle arrest in gastric cancer cell lines. Moreover, our in-vivo experiments demonstrated menadione inhibiting tumor development and progression. Conclusions: We suggest this compound may be an important ally of chemotherapeutics in the treatment of gastric cancer. In addition, CDC25B has proven to be an effective target for investigation and development of new therapeutic strategies for this malignancy.